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INTRODUCTION
Multiple Sclerosis (MS) is the most commonly acquired autoimmune disease, currently affecting over 400,000 people in the US, and 2 million people worldwide. MS is characteristic of demyelination in the central nervous system (CNS), a process largely associated with the breakdown and loss of myelin sheaths. As a result, the efficient conduction of axonal impulses is hampered, leading to various neurological disabilities and cognitive impairment. In the healthy CNS, demyelinated axons can be reinvested with new myelin sheaths through a highly effective regenerative process. The remyelination process involves the recruitment of oligodendrocyte precursor cells, which are subsequently activated and distributed to the damaged axons. However, the remyelination process is often disrupted in MS. This leads to incomplete myelin repair, and subsequent irreversible axonal damage.
In vivo imaging of demyelination and remyelination in the CNS, especially changes in the spinal cord is of particular importance as much of the physical disability and cognitive impairment in MS are associated with myelin damage (Bot et al., 2004; Ciccarelli et al., 2007) .
For this reason, our laboratory has been developing myelin-specific radiotracers for in vivo PET imaging of myelination. Over the past decade, we have identified several lead compounds that readily enter the brain and selectively localize in the myelinated white matter Wu et al., 2006; Wu et al., 2008; Wang et al., 2009; Wang et al., 2010b; Wang et al., 2010a; Wu et al., 2010; Wang et al., 2011) . In our previous studies, one of the lead compounds (MeDAS) has been radiolabeled with positron-emitting carbon-11, and used for PET imaging of myelination (Wu et al., 2008; Wu et al., 2010) . We demonstrated that [
11 C]MeDAS can readily penetrate the blood-brain barrier (BBB) and localize in various brain regions in proportion to the extent of myelination. [ 11 C]MeDAS-PET can be used to quantitatively detect myelin changes in the brain in mouse models with myelin pathology (Wu et al., 2010) .
Encouraged by the results, we evaluated the potential of [ 11 C]MeDAS-PET as a sensitive and specific imaging marker to detect demyelination and remyelination in the spinal cord, which would be a very powerful tool for screening novel therapies aimed at myelin repair. In this work, we report in vivo characterization of [ 11 C]MeDAS-PET in the spinal cord in different animal models such as lysolethicin (lysophosphatidyl chorine, LPC) induced rat model of focal demylination, and experimental autoimmune encephalomyelitis (EAE) rat models.
Subsequently, we conducted the first image-guided myelin repair therapy based on hepatocyte growth factor (HGF), which has been identified as a key component in mesenchymal stem cells In the first year of this project, we have reached all the milestones listed in Specific Aim 1. In the second year, we report our progress on the tasks listed in Specific Aim 2.
MATERIAL AND METHODS
Animal surgery and care was performed in accordance with the Institutional Animal Care and Use Committee of Case Western Reserve University.
Induction of focal demyelination in the spinal cord
In this model, LPC was directly injected into the spinal cord of Sprague-Dawley (SD) female rats (8-10 weeks old, 220-240 g) as reported (Kerstetter et al., 2009 ) . Animals were anesthetized using a mixture of rodent cocktail. For post-operative pain relief, Torbugesic (2 mg/kg) was subcutaneously administered prior to surgical procedure. A T10 laminectomy was performed by first making lateral longitudinal incisions in the paraspinal muscles from the middle of T-11 through the middle of T-12. A beveled microcapillary glass needle attached through small diameter tubing to a microinjection system (using a 10 µl Hamilton syringe) was then directed 1 mm into the dorsal column of the spinal cord with the aid of a Stoelting stereotaxic manipulator. LPC was injected into the dorsal column in a dose of 1.5 µl at 1% concentration, at a rate 0.25 µl/min. It was then necessary to wait 2-3 additional minutes prior to dose administration before removing the needle, to ensure there was no backflow of the solution. The animals were then allowed to recover in a clean cage sitting on a heating pad.
Induction of EAE in rats
Two sets of 8-week old female rats, 3 Lewis and 3 SD, were acquired from Charles River Laboratories, in Wilmington MA. They were kept in our animal facility for one week after arrival, before immunization. Recombinant myelin oligodendrocyte glycoprotein (rMOG 1-125, from Biogen Idec.) inoculum was freshly prepared by initially diluting the rMOG in 0.01M phosphate buffered saline (PBS, pH 7.4) to a final concentration of 2 mg/ml. Then, equal volumes of MOG/PBS and Complete Freund's Adjuvant were mixed thoroughly (CFA (2mg/ml), Chondrex, Inc, WA). The emulsion was gently centrifuged, and loaded slowly into a 1-ml syringe for subcutaneous injection. Rats were anesthetized with rodent cocktail before emulsion injections, and administered 100 µl of inoculum by intradermal injection at the base of the tail. Each rat received 50 µg of rMOG 1-125.
After MOG induction, animals were weighed and scored daily for signs of EAE according to the following scale: 0, no disease; 1, tail paralysis; 2, hind limb weakness; 3, hind limb paralysis; 4, hind limb paralysis and forelimb weakness; 5, moribund or dead.
Induction of rat lipopolysaccharide (LPS) neuroinflammation model
Female SD rats (n=3, 6-8 weeks of age) were anesthetized with rodent cocktail and positioned in a stereotaxic frame (Stoelting). The scalp was incised and retracted so the cortex and corpus callosum could be targeted using the following stereotaxic coordinates: (relative to bregma)
anterior-posterior (AP), 3.0 mm; medial-lateral (ML), 1.0mm; and dorsal-ventral (DV), 2.0 mm for cortex, and AP, 0.0 mm; ML, 2.0mm; and DV, 4.5 mm for corpus callosum. Two small holes were drilled in the skull, and a 33S gauge needle attached to a 10 µL Hamilton Syringe was lowered into the cortex and corpus callosum via the prior coordinates. A mini injector pump (Stoelting) controlled the infusion of 3 µL of LPS (E.coli, serotype 055:B5, 1mg/ml) at a rate of 0.25 µL/min, after which the needle was left in place for 2 min to prevent liquid reflux out of the brain parenchyma. The incision was then closed, and the animals were allowed to recover on a heating pad.
Histopathology
After microPET studies, histopathological studies were conducted. The animals were killed by a transcardial perfusion of saline followed by 4% polyformaldhyde (PFA) under anesthesia. The spinal cord and brain were carefully removed and postfixed in 4% PFA overnight, followed by 10%, 20% and 30% sucrose solution. They were then sectioned at 20µm on a cryostat, and mounted directly onto Superfrost Plus microscope slides. The slides were then subject to either neuroinflammation staining or myelin staining using Black gold, Luxol Fast Blue, or MeDAS staining as previously described (Mi et al., 2007; Wu et al., 2008; Wang et al., 2009 ).
Neuroinflammation staining
After the perfused tissue was cryoprotected in sucrose and frozen in OCT, 20uM serial sections were made on a Microm HM525. They were air-dried and kept at -20 o C until staining.
The samples were brought to room temperature and allowed to air-dry again, followed by rehydration in PBS. The PBS was removed, and the sections were blocked with 5-10% Normal
Goat Serum in 0.1% Triton-X 100 in PBS for one hour at room temperature. The antibodies, IBA1 (Rabbit polyclonal, Wako Cat. #019-19741) or GFAP (Rabbit polyclonal, Dako Z0334), were diluted 1:500 in block, and the sections were incubated overnight at 4 o C. The next day, the sections were rinsed, incubated 1.5 hours in the secondary antibody (Invitrogen goat antiRabbit IgG Alexa-594), then rinsed again and mounted in Vectashield. The sections were imaged on a Leica DM 5500B microscope, using a Leica DFC 500 camera.
Ex vivo fluorescent tissue staining of myelin
A dose of (25 mg/kg) of MeDAS was administered via tail-vein injection to a Female SD rat. At 2 hours post-injection, the rat was deeply anesthetized and perfused transcardially with saline and 4% paraformaldehyde (PFA). The brain and spinal cord were removed and postfixed by immersion in 4% PFA overnight, then dehydrated in 30% sucrose solution and embedded in a freezing compound (OCT, Fisher Scientific, Suwanee, GA).They were cryostat sectioned at 20
µm on a microtome, and mounted on superfrost slides (Fisher Scientific) with fluoromount-G mounting media (Vector Laboratories, Burlingame, CA). Due to the fact that MeDAS is inherently fluorescent, MeDAS staining of myelin was able to be directly examined under a Leica DRMB microscope equipped for fluorescence.
HFG treatment
In these studies an LPC lesion was induced as described above, and the animals were then treated with 2 doses of HGF systemically. Because there is an initial immunological response to the demyelinating lesion, delivery of the first dose was delayed for 4 days after lesion induction. Animals were randomly assigned to either control (saline, n=6) or experimental (HGF treatment, n=8) groups. The experimental group received 0.4 and 0.8µg/Kg of HGF via tail vein injection on days 4, 6, and 12 prior to lesion development. The controls received an equivalent volume of saline, and the animals were imaged on days 7, 14, and 21 post LPC treatment.
MicroPET/CT imaging of spinal cord and data acquisition
PET imaging of [ 11 C]MeDAS was performed using a Siemens Inveon microPET/CT scanner in the Case Center for Imaging Research. For better anatomic localization, CT co-registration was applied. For LPC treated rats, PET/CT scans were performed on days 0, 7, 14, and 21, following LPC injections in spinal cord. For EAE rats, PET scans were performed on day 0, and the first, second, and third disease episodes after MOG induction. The rats were fasted overnight prior to imaging, but had access to water. Their diet was then replenished after imaging. Before PET imaging, CT scout view was taken to ensure most of the vertebrae, especially the ilium, were placed in the co-scan field of view (FOV) where the highest image resolution and sensitivity is achieved. Approximately 37 MBq of [ 11 C]MeDAS was injected through the tail vein, and dynamic microPET data acquisition was performed in a list mode immediately. During the scans, body temperature of the anesthetized rats was maintained at 34+/-2°C with a heating lamp. Once the dynamic acquisition was done, a CT acquisition scan was performed for attenuation correction.
Quantitative image analysis
Quantitative image analysis of the uptake of [ 11 C]MeDAS in spinal cord was performed using Carimas II software. This program allows an ROI to be extrapolated from the reconstructed microPET image frames in order to determine the SUV in a specific region. Based on the PET and CT co-registered images, the rat's ilium was used as a marker to accurately identify vertebrae. For LPC treated rats, lesion vertebrae (Thoracic 11 and Thoracic12) were then defined as the regions of interest (ROI). For EAE rats, every single rat vertebrae (from Thoracic 8 to Lumbar 1) was defined as a ROI. The radioactivity data were decay-corrected and normalized by the body weight of the rats, and amount of 
MicroPET imaging in acute neuroinflammation rat model and data acquisition
The rats with the brain as the desired FOV were placed in an Inveon microPET scanner under anesthesia. After a 10 min transmission scan with a Co-57 source, 37 MBq of [ 11 C]MeDAS was administered via tail vein injection, and immediately followed by a dynamic acquisition of up to 90 min. A two-dimensional OSEM algorithm was used for image reconstruction. Decay, attenuation, and scatter correction were all performed during the image histogram and reconstruction processes. For better anatomic localization, a MRI scan was also performed.
After microPET imaging, the same bed was transferred to a MRI scanner (Bruker Biospin 7.0T, Billerica, MA). The rat's head was well positioned in the center of the rat coil. A rapid- 
Statistical analysis
In this study, all data is expressed as a mean±SD. A Student's t test was used to evaluate if there is any significant difference between each groups of studies. A p value of <0.05 was accepted as significant.
RESULTS

In vitro tissue staining of the spinal cord
MeDAS is a fluorescent compound with maximum excitation and emission wavelengths of 363 and 419 nm, respectively (Wu et al., 2008) . So the myelin binding property of MeDAS can be evaluated based on fluorescent microscopy. We thus conducted fluorescent tissue staining by incubating spinal cord tissue sections with a solution of MeDAS in 10% DMSO. For this purpose, a series of axial sections of the spinal cord were prepared so that both myelin-rich white matter and myelin-deficient gray matter could be visualized. We then conducted fluorescent tissue staining using spinal cords taken from wild-type, LPC-treated, and EAE rats.
In addition, each MeDAS staining was correlated with Black-Gold staining, which was performed on adjacent sections. At a 10 µM concentration, MeDAS selectively stained the spinal cord white matter. In contrast, much less staining of MeDAS was observed in the gray matter. In the wild-type spinal cord, MeDAS staining showed a fluorescent pattern that was consistent with Black-Gold staining, suggesting that MeDAS's retention is proportional to the myelin distribution throughout the spinal cord (Figures 1 A and 1B) . 
Biodistribution study
To explore the potential of MeDAS as a radiotracer for in vivo PET imaging, we radiolabelled 
In vivo competition studies
To further determine the in vivo binding specificity of MeDAS for myelin, we conducted in vivo competition studies using a previously developed myelin-binding agent ( BMB), as a blocking agent, which has shown high affinity for myelin . Before BMB treatment, we conducted [ 11 C]MeDAS-PET imaging in a wild-type rat, and the radioactivity concentration in the various brain regions such as frontal cortex (FC), corpus callosum (CC), temporal lobe (TL), and cerebellum (CB) were quantified. As shown in Figure 3A , the uptake of 
Effects of neuroinflammation on PET imaging of demyelination
In MS pathology, both demyelination and neuroinflammation are present in the CNS. To determine if neuroinflammation has any effects on the [ 11 C]MeDAS uptake, we prepared an acute neuroinflammation model by stereotaxic injection of LPS to the rat brain (Wenk et al., 2004) . Subsequent histological analysis showed that one day after injection, profound inflammation was developed in the rat brain while myelin sheaths remained intact.
Immunohistology showed profound microglia activation and macrophages in the brain by IBA1 staining (Figure 4A and 4E) . A reactive form of astrocytes was also detected by GFAP staining (Figure 4B and 4F) . In the meantime, the myelin integrity remained intact as demonstrated by Luxol Fast Blue staining ( Figure 5C and 5G) , and in vitro MeDAS staining ( Figure 4D and 4H) . Using this neuroinflammation rat model, we conducted PET studies to determine [ 11 C]MeDAS uptake before and after the inflammation was induced. As shown in Figure 4I and 4J, [ 11 C]MeDAS uptake was practically identical before and after LPS treatment.
Thus, induction of inflammation did not alter the pharmacokinetics of [ 11 C]MeDAS in the brain.
These studies suggested that [ 11 C]MeDAS-PET is a specific imaging marker of demyelination, but not neuroinflammation. 
Longitudinal PET imaging of the spinal cord in a LPC rat model
We then evaluated the ability of [ 11 C]MeDAS-PET to longitudinally assess myelin content in the spinal cord in vivo. To quantitatively characterize demyelination and remyelination, we first induced a focal demyelinated lesion (T11-12) by stereotactic injection of LPC to the spinal cord.
The rat was then subjected to a serial PET/CT imaging at the peak of demyelination (7 days post injection), and during the course of remyelination (14 and 21 days post injection). As shown in Figure 5A , the rat spinal cord was readily visualized by 
Longitudinal PET imaging of the spinal cord in EAE rat model
While the LPC model represents pure demyelination/remyelination, EAE is the animal model that closely mimics the MS pathology. We thus conducted a series of [ 11 C]MeDAS-PET imaging in an EAE rat model to longitudinally monitor myelination in the spinal cord. In this study, EAE was induced by immunizing 3 SD rats and 3 Lewis rats with MOG1-125 peptide.
Starting at day 7 after immunization, the SD and Lewis rats developed paralysis of hind limbs, with an EAE score reaching 3.0 or above in a relapsing and remitting pattern. In this study, we conducted longitudinal PET imaging at three time remitting points of the disease. Figure 8C ). This is particularly apparent at the third episode when the EAE symptom was most severe. Unlike the EAE SD rats, the EAE Lewis rats showed the most difference in the lumbar region between L1 and L6 ( Figure 8D ). Post-mortem histochemical staining using both MeDAS and Black-Gold displayed significantly low fluorescence in the white matter of the spinal cord (Figure 2E and 2F) . 
Limit to detect demyelination and remyelination
The limit to detect demyelination and remyelination by [ 11 C]MeDAS-PET is determined by multiple factors, including the detection efficiency of PET scanner, specific activity of radioligands, and binding affinity for myelin. Our previous study showed that binding affinity (Kd) of such type of myelin-imaging agents was in the range of 1 nM with a B max of 17pmol/mg (Wang et al., 2009 
molecular uptake brain activity specific
Image-guided myelin repair therapy
Based on the longitudinal studies, we conducted the first image-guided myelin repair therapy in a rat model of focal demyelination to monitor myelin changes in the spinal cord and determine the dose response of HGF, a multifunctional growth factor that has been proven to be the effective component in MSC therapy of myelin repair (Bai et al., 2012) . In this study, rats were first treated with LPC to induce demyelination in the spinal cord. On days 7 and 9, the rats were sequentially treated with HGF, and imaged by [
11 C]MeDAS-PET on days 7, 14, and 21. At a dose of 100 ng/rat or 0.4 µg/kg, the HGF-treated rats displayed an increased [ 11 C]MeDAS uptake in the spinal cord compared to the control rats. Quantitative analysis showed the HGF treatment caused the average uptake in the demyelinated regions to be 31% and 14% greater at day 14 and 21 respectively, when compared with day 7 (Figure 9 ). When the rats were treated with a higher dose of HGF (i.e. 200 ng/rat or 0.8 ug/kg), the maximal remyelinating effect was observed to be 33% and 35% on days 14 and 21, respectively. Note there is only a significant difference in the amount of remyelination on day 21, on day 14, the difference in remyelination provided by the additional dose of HGF is not significant. The imaging results
were confirmed by double-blinded immunohistochemical observations of postmortem tissue sections harvested at each time point (Bai et al., 2012) . Based on the biodistribution, dosimetry was estimated using OLINDA/EXM (Stabin et al., 2005) software. Based on an extrapolation of the animal data to humans, the radiation doses estimated for various human organs are summarized in Table 2 . Table 2 . Organ and whole body extrapolated human dosimetry estimation.
Acute Toxicity study
Following dosimetry estimation, we also evaluated the acute toxicity in mice. A total of 30 mice were divided into 5 groups, which were injected with escalating doses ranging from 82 mg/kg to 168 mg/kg. Based on the survival percentage, we calculated the LD 50 of MeDAS as 141 mg/kg, which is well in the safety margin, as it is in the 6 orders of magnitude higher than the amount needed for the in vivo PET imaging studies.
DISCUSSION
Current therapeutic strategies primarily target the immunopathological basis of demyelination.
The outcome from this approach has not been particularly successful, as most therapies continue to be directed toward widespread immuno-suppression, and do little to promote long lasting repair. As such, they are of limited value for supporting long-term functional restoration.
For long term functional recovery in patients with MS and related acquired demyelinating diseases, tremendous efforts have been made to utilize the information generated from pathobiological studies on the development of myelinating oligodendrocyte cells of the CNS, to the identification of targets and characterization of new therapeutic approaches towards promoting lasting remyeliantion in the adult CNS.
For drug discovery and development in myelin repair therapy, one major challenge has been assessing and quantifying changes in myelin content in vivo. To date, magnetic resonance imaging (MRI) has been the primary tool for diagnosing and monitoring the demyelinating conditions in MS. Unfortunately, any change in signal intensity on a dual echo T2-weighted sequence reflects a change in tissue water content, which is a non-specific measure of the overall changes in macroscopic tissue injury and ranges from edema and inflammation, to demyelination and axonal loss. As a result, MRI changes do not specifically reflect changes in demyelination and remyelination. It is thus essential to develop a measure that will effectively correlate clinical outcomes directly with myelin content. For this reason, we propose to detect and quantify myelin changes based on PET. PET imaging is a noninvasive imaging technique capable of direct characterization and quantification of biological processes at the molecular level (Phelps, 2000) . It has become one of the most important clinical techniques in the diagnosis, prognosis, and monitoring of disease progression. This powerful imaging technique is used in conjunction with trace amounts of positron-emitting radiotracers that are specific for targets of interest.
For in vivo detection and quantification of myelin changes, radiotracers must readily enter the brain and specifically bind to myelin sheaths. To date, lack of myelin-specific imaging radiotracers has hampered the application of PET in monitoring demyelination and remyelination. As a result, PET study in MS is limited to the characterization of neuroinflammation using [ 18 F]FDG for glucose metabolism or [ 11 C]PK11195 for peripheral benzodiazepine receptors (PBR) mediated microglia activation (Cuzner, 1997; Wilms et al., 2003; Chen and Guilarte, 2006; Buck et al., 2012) . However, such radiotracers are not specific for the characterization of demyelination and remyelination, so they do not provide any correlation of disease progression in MS. Most recently, a F-18 labeled mitochondrial 18kDa translocator protein (TSPO) radioligand termed [ 18 F]DPA-714, has also been developed to image microglial/macrophage activation present in the experimental autoimmune encephalomyelitis (EAE) rat model (Abourbeh et al., 2012) . Similar to PBR, TSPO only mediates neuroinflammation (Winkeler et al.; Banati, 2002; Dolle et al., 2009 A new strategy is to develop therapeutic agents that are aimed at stimulating remyelination in damaged neural tissues. To date, the development of such myelin repair therapeutics for MS has been hampered by the lack of imaging approaches that allow for direct detection and quantification of myelin changes in a longitudinal manner. In order to meet this challenge, we developed a series of radiotracers for PET imaging of myelination. To identify the most promising PET imaging markers for downstream clinical studies, we used the following set of quantitative acceptance criteria to guide our evaluation processes: 1) High brain uptake at early time points following i.v. injection. At 5 min post injection, the brain concentration of probe should reach 5% ID/g; 2) Average retention in white matter should be at least 20%
higher than that in the adjacent gray matter in the spinal cord; 3) In animal models of MS,
CONCLUSION
The studies described above represent a unique imaging-guided approach to monitor disease and repair processes in demyelinating conditions in the CNS, with the absence of invasive surgeries or biopsies. The major advance in being able to utilize our newly developed myelinimaging technique to quantify local levels of myelination, will for the first time, allow the development of therapeutics that are directly focused at recovery of lost neural tissue. Because myelin repair is critical for sustained functional recovery, the ability to directly track myelin levels in defined regions of the human CNS will allow us to assess the efficacy of new therapeutics in promoting myelin repair. Thus, the threshold for developing new MS therapeutics will be significantly reduced, and this application holds the promise of allowing new therapeutic development to proceed in a highly accelerated manner. As a consequence, the impact on MS patients will be profound as this novel approach could potentially revolutionize therapeutic development for demyelinating diseases, and hasten their widespread clinical application.
